The Searle Company Limited (SEARL): 1QFY25 Corporate Briefing Takeaways – By Taurus Research
Nov 27 2024
Taurus Securities
- SEARL is the second-largest pharmaceutical company in Pakistan in terms of units sold. It holds the position of #2 in market volume and #5 in terms of market value within the pharmaceutical sector, with a market share of 8.3% by volume and 4.8% by value. The Company operates across a diverse range of sectors, including pharmaceuticals, biopharmaceuticals, nutraceuticals, medical devices, and therapeutic areas such as allergy, antibiotics, angiology, and gastroenterology.
- SEARL’s manufacturing capabilities are distributed across seven state-of-the-art facilities, with four located in Karachi and three in Lahore. These facilities are dedicated to different product categories, ensuring efficiency and specialization in production.
- For the first quarter of FY25, SEARL reported a revenue of ~PKR 7.6Bn, reflecting a 12% decline compared to ~PKR 8.7Bn in the SPLY. This decrease is primarily attributed to the separation of the SPL business, which previously contributed ~PKR 2.1Bn per quarter to SEARL's consolidated revenue. Despite this dip in revenue, the Company achieved earnings of PKR 0.8 per share for 1QFY25.
Current:
Open:
Volume:
Change: ()
High:
Low:
52 Week High:
Vol Avg(12 m):
Free Float:
52 Week Low:
Market Cap:
Total Share:
Relative Strength Index (RSI)
RSI:
MACD Signals
MACD DAILY:
MACD WEEKLY:
Simple Moving Avg (SMA)
SMA(10):
SMA(30):
SMA(60):
SMA(200):
Performance
One Month:
Three Months:
Six Months:
Twelve Months:
Support & Resistance
Support 1:
Resistance 1:
Support 2:
Resistance 2:
High & Lows
Period
High
Low